Economic examination of cefoperazone therapy

Area of Science:

• Pharmacoeconomics
• Infectious Diseases
• Healthcare Management

Background:

• Traditional antimicrobial cost assessments (per gram, dose, or day) may not reflect overall healthcare expenditure.
• Evaluating the total cost of care is crucial for informed clinical and economic decision-making in healthcare settings.

Purpose of the Study:

• To compare the total direct costs of care for patients receiving cefoperazone versus alternative initial antibiotic therapies.
• To identify specific cost drivers associated with different antibiotic treatment regimens.

Main Methods:

• Retrospective review of medical records for 1137 patients across 35 hospitals.
• Analysis of direct medical costs, including antibiotic acquisition, drug administration, laboratory testing, and room and board charges.
• Regression analysis to compare cost factors between the cefoperazone group and a control group receiving alternative agents.

Main Results:

• Cefoperazone therapy was associated with lower costs in drug administration (-$63), laboratory testing (-$9), and room and board (-$80), though not statistically significant for the latter two.
• Antibiotic acquisition costs were higher by $24 per patient in the cefoperazone group (p < 0.01).
• Overall total costs averaged $3073 per cefoperazone patient versus $3228 per control patient (p = 0.20), indicating a trend towards lower total costs with cefoperazone.

Conclusions:

• Cefoperazone as initial therapy demonstrates a trend towards reduced total direct costs of care compared to alternative agents.
• The study underscores the inadequacy of traditional antimicrobial cost metrics in the current healthcare cost-containment environment.
• Practitioners should consider a holistic approach to cost evaluation, examining all components of care to optimize antimicrobial selection and patient outcomes.